Search

You searched for "ophthalmic disease"

912 results found

The Case of Dr Bawa-Garba – Where does the buck stop?

1 August 2018 | | EYE - Vitreo-Retinal, EYE - General
The case of Hadiza Bawa-Garba has left all of us in the UK medical profession with an uncomfortable taste in our mouths. We all know that we work under pressure and we will inevitably make mistakes. We all know that...

The management of retinal vein occlusions: a summary

1 February 2015 | | EYE - Cataract, EYE - Refractive, EYE - Cornea, EYE - Imaging, EYE - Vitreo-Retinal, EYE - General
Retinal vein occlusions (RVO) are the most common cause of visual loss from retinal vascular disease second to diabetic retinopathy. Vision is lost due to ischaemia, macular oedema and / or haemorrhage which ultimately effects a patient’s quality of life...

Understanding amniotic membrane grafts

1 June 2019 | | EYE - Cornea, EYE - General
Safa Elhassan gives a brief review of amniotic membrane grafts and their application in theatre and clinic-based settings. Amniotic membrane (AM) transplant has been an established adjuvant treatment for many corneal, conjunctival and scleral disorders in ophthalmic clinical practice with...

Case series of toxic anterior segment syndrome

1 August 2019 | | EYE - Cataract, EYE - Refractive, EYE - General
Herein we report two cases of toxic anterior segment syndrome (TASS) following uneventful cataract surgery. Both patients presented 24 hours after their uneventful operations with painless blurred vision in the operated eye. The inflammatory reaction was controlled successfully with an...

Understanding and confronting bacterial endophthalmitis

2 December 2019 | | EYE - Cornea, EYE - Vitreo-Retinal, EYE - General
Abdus Samad Ansari highlights the importance of early recognition of this condition using an unusual presentation. Endophthalmitis is a medical emergency with devastating consequences. Despite adequate treatment, severe cases frequently result in permanent blindness. Endophthalmitis involves inflammation of both the...

Refined glaucoma referral practice offers prospect of improved capacity and expanded role for primary eye care professionals

1 February 2018 | | EYE - Glaucoma
Glaucoma is the most frequent cause of irreversible blindness worldwide and the second leading cause of blindness in the UK [1,2]. The global prevalence of glaucoma in 2010 was approximately 3.5% for people aged 40-80 years, according to Jonas et...

Eye research: where next?

1 December 2017
Eye research in the UK is underfunded relative to other areas of medical research and general awareness of sight loss and its prevention remains poor, messages that were reinforced in presentations and discussions during a recent research summit meeting in...

Considerations in the management of retinal disorders

1 October 2017 | | EYE - Vitreo-Retinal
Vision research presentations and publications explore practice considerations in the management of AMD and diabetic retinopathy. Over the past two decades in Europe there has been a decreasing prevalence of age-related macular degeneration (AMD) and an improvement in visual acuity...

#KnowYourDrops: breaking down barriers to poor compliance

1 June 2017 | | EYE - Glaucoma
Award-winning* #KnowYourDrops eye drop compliance campaign helps patients for World Glaucoma Week to achieve medicines optimisation in ophthalmology. The #KnowYourDrops campaign is fast becoming an internationally recognised model to help support healthcare professionals, with the provision of better tailored ophthalmic...

The Global Vision Database

1 December 2015 | | EYE - General
The overall goal of the Global Vision Database (GVD) [1] is to develop and deploy new and improved evidence on the prevalence of blindness and vision impairment (VI) globally. It is a repository which allows us to assess the causes...

Strategies for managing neovascular AMD and DMO in routine clinical care

1 October 2015 | | EYE - Vitreo-Retinal
Treatment practice in the management of neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DMO) illustrate increasing adoption of patient-tailored treatment approaches based on initial diagnosis and regular monitoring of imaging and visual outcomes in routine clinical care. The...

NICE drugs: an update on what’s good to go

1 June 2014 | | EYE - Neuro-ophthalmology, EYE - Vitreo-Retinal
Treatment options recommended by the National Institute for Health and Care Excellence (NICE) must be readily available for use in the NHS of England and Wales. This article provides an overview of recent guidance from NICE and summary advice issued...